Taysha IPO Presentation Deck

Focused on achieving near-term milestones and building long-term value 110 GM2 gangliosidoses to enter the clinic in 2020 CLN1 expected to dose first patient 2021 4 INDs expected to be submitted by the end of 2021 State-of-the-art GMP manufacturing online in 2020 Numerous value generating catalysts over the next 18 months 43

View entire presentation